tirzepatide surpass-4 versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial Tirzepatide reduces albuminuria among adults

Start with our short online consultation

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

We are an independent company and are not affiliated with, endorsed by, authorized by, or in any way officially connected with Meta Platforms, Inc., Facebook, Instagram, or any of their subsidiaries or affiliates

The Tirzepatide Oral Protocol from PlexusDx is a compounded GIP/GLP-1 dual agonist prescribed by licensed providers

Body composition sometimes changes without dramatic scale movement

A supervised program offers real advantages: Both are once-weekly GLP-1 injections that reduce appetite and support weight loss